{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:32:21Z","timestamp":1777901541452,"version":"3.51.4"},"reference-count":47,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ijrobp.2025.12.018","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:06:52Z","timestamp":1766189212000},"page":"1421-1430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Multi-institutional Analysis of MR-Guided Single-Fraction Stereotactic Ablative Body Radiation Therapy: Feasibility, Safety, and Efficacy"],"prefix":"10.1016","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9086-2066","authenticated-orcid":false,"given":"Frederik","family":"Fuchs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupesh","family":"Kotecha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muni","family":"Rubens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mukesh","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn E.","family":"Mittauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sina","family":"Mansoorian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeel","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noah","family":"Kalman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurelie","family":"Gaasch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian N.","family":"Marschner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nema","family":"Bassiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Rogowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chukwuka","family":"Eze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus","family":"Belka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Chuong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.12.018_bib0001","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S1470-2045(15)70168-3","article-title":"Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: A pooled analysis of two randomised trials","volume":"16","author":"Chang","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0002","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ijrobp.2016.10.041","article-title":"Multi-institutional experience of stereotactic ablative radiation therapy for stage I small cell lung cancer","volume":"97","author":"Verma","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0003","doi-asserted-by":"crossref","DOI":"10.1177\/1533033818783904","article-title":"Clinical outcomes of stereotactic body radiotherapy for patients with stage I small-cell lung cancer: Analysis of a subset of the Japanese radiological society multi-institutional SBRT study group database","volume":"17","author":"Shioyama","year":"2018","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0004","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.ijrobp.2012.07.2354","article-title":"Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly","volume":"84","author":"Shirvani","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0005","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.ijrobp.2009.07.1751","article-title":"Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: Can SBRT be comparable to surgery?","volume":"81","author":"Onishi","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0006","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamaoncol.2024.5403","article-title":"Stereotactic body radiotherapy vs sorafenib alone in hepatocellular carcinoma: The NRG oncology\/RTOG 1112 phase 3 randomized clinical trial","volume":"11","author":"Dawson","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0007","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1200\/JCO.2015.61.4925","article-title":"Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma","volume":"34","author":"Wahl","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0008","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1470-2045(24)00020-2","article-title":"Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): A non-randomised phase 2 trial","volume":"25","author":"Siva","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0009","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(23)00513-2","article-title":"Stereotactic body radiotherapy for primary renal cell carcinoma: A systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS)","volume":"25","author":"Siva","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0010","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0011","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: A multicentre, randomised, controlled, phase 2 study","volume":"17","author":"Gomez","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0012","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.22.00644","article-title":"Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: Analysis of STOMP and ORIOLE trials","volume":"40","author":"Deek","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0013","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: A phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0014","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1097\/JTO.0b013e318074de34","article-title":"Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: Updated results of 257 patients in a Japanese multi-institutional study","volume":"2","author":"Onishi","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0015","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.3390\/cancers15102786","article-title":"Long-term clinical results of MR-guided stereotactic body radiotherapy of liver metastases","volume":"15","author":"Weykamp","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0016","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.radonc.2021.06.005","article-title":"Ablative radiotherapy for liver tumors using stereotactic MRI-guidance: A prospective phase I trial","volume":"170","author":"van Dams","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0017","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.ijrobp.2018.11.051","article-title":"Long-term follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer","volume":"103","author":"Videtic","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0018","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.semradonc.2014.02.008","article-title":"The ViewRay system: Magnetic resonance-guided and controlled radiotherapy","volume":"24","author":"Mutic","year":"2014","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0019","first-page":"98","article-title":"Technical design and concept of a 0.35 T MR-Linac","volume":"18","author":"Kl\u00fcter","year":"2019","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0020","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.ijrobp.2018.05.048","article-title":"MR-guided gated stereotactic radiation therapy delivery for lung, adrenal, and pancreatic tumors: A geometric analysis","volume":"102","author":"van S\u00f6rnsen de Koste","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0021","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.adro.2020.06.011","article-title":"Single-fraction stereotactic body radiation therapy: A paradigm during the coronavirus disease 2019 (COVID-19) pandemic and beyond?","volume":"5","author":"Ng","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0022","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.3390\/cancers13071523","article-title":"Feasibility and early clinical experience of online adaptive MR-guided radiotherapy of liver tumors","volume":"13","author":"Rogowski","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0023","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.prro.2020.09.005","article-title":"Ablative 5-fraction stereotactic magnetic resonance-guided radiation therapy with on-table adaptive replanning and elective nodal irradiation for inoperable pancreas cancer","volume":"11","author":"Chuong","year":"2021","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109823","article-title":"Local control and toxicity after magnetic resonance imaging (MR)-guided single fraction lung stereotactic ablative radiotherapy","volume":"187","author":"Tekatli","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0025","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ijrobp.2020.02.025","article-title":"Clinical outcomes of stereotactic MR-guided adaptive radiation therapy for high-risk lung tumors","volume":"107","author":"Finazzi","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0026","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00066-024-02328-1","article-title":"MR-guided online adaptive stereotactic body radiotherapy (MRgSBRT) of primary lung tumors and lung oligometastases","volume":"201","author":"Ugurluer","year":"2024","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0027","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.phro.2022.09.010","article-title":"Same-day consultation, simulation and lung stereotactic ablative radiotherapy delivery on a magnetic resonance-linac","volume":"24","author":"Palacios","year":"2022","journal-title":"Phys Imaging Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0028","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1200\/JCO.23.00150","article-title":"Long-term outcomes of TROG 13.01 SAFRON II randomized trial of single- versus multifraction stereotactic ablative body radiotherapy for pulmonary oligometastases","volume":"41","author":"Siva","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0029","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ijrobp.2019.08.019","article-title":"One versus three fractions of stereotactic body radiation therapy for peripheral stage I to II non-small cell lung cancer: A randomized, multi-institution, phase 2 trial","volume":"105","author":"Singh","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0030","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1016\/j.prro.2024.09.011","article-title":"Stereotactic body radiation therapy for liver metastases: Systematic review and meta-analysis with International Stereotactic Radiosurgery Society (ISRS) practice guidelines","volume":"15","author":"Franzese","year":"2025","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0031","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3857\/roj.2020.00976","article-title":"Stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of liver metastases in oligometastatic patients: Initial clinical experience","volume":"39","author":"Ugurluer","year":"2021","journal-title":"Radiat Oncol J"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0032","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.adro.2018.08.005","article-title":"A multi-institutional experience of MR-guided liver stereotactic body radiation therapy","volume":"4","author":"Rosenberg","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0033","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.radonc.2017.11.032","article-title":"Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen","volume":"126","author":"Henke","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0034","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3390\/jcm12031183","article-title":"Stereotactic MR-guided radiotherapy for liver metastases: First results of the Montpellier Prospective Registry Study","volume":"12","author":"Bordeau","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0035","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.ijrobp.2025.03.030","article-title":"Stereotactic magnetic resonance guided adaptive radiation therapy in one fraction: A multicenter, single-arm, phase 2 trial","volume":"122","author":"Chuong","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0036","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s12885-018-4191-2","article-title":"The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): Patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases","volume":"18","author":"Andratschke","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107284","article-title":"Stereotactic body radiotherapy for lung oligo-metastases: Systematic review and international stereotactic radiosurgery society practice guidelines","volume":"182","author":"Mayinger","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0038","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ijrobp.2016.03.050","article-title":"Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes after stereotactic body radiation therapy","volume":"95","author":"Ahmed","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0039","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ijrobp.2017.07.030","article-title":"Local control outcomes using stereotactic body radiation therapy for liver metastases from colorectal cancer","volume":"99","author":"Joo","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0040","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.lungcan.2018.06.018","article-title":"30 Gy single dose stereotactic body radiation therapy (SBRT): Report on outcome in a large series of patients with lung oligometastatic disease","volume":"122","author":"Osti","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0041","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1186\/s12885-020-06906-1","article-title":"Stereotactic robotic body radiotherapy for patients with oligorecurrent pulmonary metastases","volume":"20","author":"Berkovic","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0042","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ijrobp.2017.02.093","article-title":"Stereotactic ablative radiation therapy for pulmonary metastases: Histology, dose, and indication matter","volume":"98","author":"Helou","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0043","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.prro.2015.10.011","article-title":"Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases","volume":"6","author":"Goodman","year":"2016","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0044","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13014-018-0969-2","article-title":"Stereotactic body radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch\u00ae patient registry","volume":"13","author":"Mahadevan","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0045","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.ijrobp.2023.12.035","article-title":"Quantifying intrafraction motion and the impact of gating for magnetic resonance imaging-guided stereotactic radiation therapy for prostate cancer: Analysis of the magnetic resonance imaging arm from the MIRAGE phase 3 randomized trial","volume":"118","author":"Neylon","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0046","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jtho.2021.03.019","article-title":"The HILUS-trial-a prospective nordic multicenter phase 2 study of ultracentral lung tumors treated with stereotactic body radiotherapy","volume":"16","author":"Lindberg","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.018_bib0047","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ijrobp.2008.01.051","article-title":"Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer","volume":"72","author":"Schellenberg","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625066052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625066052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T13:05:11Z","timestamp":1773752711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301625066052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0360301625066052"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.12.018","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multi-institutional Analysis of MR-Guided Single-Fraction Stereotactic Ablative Body Radiation Therapy: Feasibility, Safety, and Efficacy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}